Ranolazine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Ranolazine
- Ranolazine: From an Undocumented Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
Ranolazine: From an Undocumented Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
The evidence pack does not currently document Ranolazine’s original licensed indication or mechanism of action. The TxGNN model predicts a possible new role in Nephrogenic Syndrome of Inappropriate Antidiuresis, but this prediction is currently supported by no registered clinical trials and no published literature — it rests on the computational model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the evidence pack (no UK licence text available) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Ranolazine is not currently available in this evidence pack, and no original indication text has been supplied. As a result, it is not possible to construct a mechanistic rationale linking Ranolazine to nephrogenic syndrome of inappropriate antidiuresis at this time — the repurposing_rationale fields (mechanistic link, similarity to original indication) are explicitly marked as pending in the source data.
The predicted association currently derives solely from the TxGNN knowledge-graph model score (99.65%, rank 3973), without corroborating clinical trial data, published literature, or an established pharmacological mechanism. This should be treated as a hypothesis-generating signal only, not as evidence of clinical plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Ranolazine currently holds no UK marketing authorisations in this evidence pack (market status: not marketed; total licences: 0). No product or indication information is therefore available to summarise.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate lacks the minimum data required for a safety and mechanistic assessment — original indication, mechanism of action, UK licensing status, and supporting clinical/literature evidence are all absent. A blocking data gap (missing SmPC-derived warnings/contraindications) prevents even an initial safety screen from being completed.
To proceed, the following is needed:
- SmPC-derived warnings, contraindications and drug interaction data (currently blocking)
- Mechanism of action data via DrugBank API query
- Confirmation of original licensed indication(s), whether in the UK or another jurisdiction
- Clinical trial and literature searches specific to nephrogenic syndrome of inappropriate antidiuresis
- UK/MHRA licensing status verification if commercial development is being considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.